Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open‐label extension study of tofacitinib in psoriasis are reported. To evaluate the long‐term safety and durability of efficacy of tofacitinib in adults with moderate to severe chronic plaque psoriasis.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with N. J.
Contact N. J., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack